[go: up one dir, main page]

WO2007053792A3 - Improving the pharmacokinetics of protease inhibitors and other drugs - Google Patents

Improving the pharmacokinetics of protease inhibitors and other drugs Download PDF

Info

Publication number
WO2007053792A3
WO2007053792A3 PCT/US2006/043400 US2006043400W WO2007053792A3 WO 2007053792 A3 WO2007053792 A3 WO 2007053792A3 US 2006043400 W US2006043400 W US 2006043400W WO 2007053792 A3 WO2007053792 A3 WO 2007053792A3
Authority
WO
WIPO (PCT)
Prior art keywords
host
pharmacokinetics
drugs
improving
pharmacokinetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/043400
Other languages
French (fr)
Other versions
WO2007053792A2 (en
Inventor
Mitchell W Mutz
Jason E Gestwicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amplyx Pharmaceuticals Inc
Original Assignee
Amplyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplyx Pharmaceuticals Inc filed Critical Amplyx Pharmaceuticals Inc
Publication of WO2007053792A2 publication Critical patent/WO2007053792A2/en
Publication of WO2007053792A3 publication Critical patent/WO2007053792A3/en
Priority to US12/151,329 priority Critical patent/US20080306098A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for modulating at least one pharmacokinetic property of a protease inhibitor upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 daltons comprising the protease inhibitor or an active derivative thereof and a pharmacokinetic modulating moiety. The pharmacokinetic modulating moiety binds to at least one intracellular protein. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host as compared to a free drug control that comprises the protease inhibitor.
PCT/US2006/043400 2005-11-05 2006-11-06 Improving the pharmacokinetics of protease inhibitors and other drugs Ceased WO2007053792A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/151,329 US20080306098A1 (en) 2006-11-06 2008-05-05 Pharmacokinetics of protease inhibitors and other drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73419705P 2005-11-05 2005-11-05
US60/734,197 2005-11-05

Publications (2)

Publication Number Publication Date
WO2007053792A2 WO2007053792A2 (en) 2007-05-10
WO2007053792A3 true WO2007053792A3 (en) 2007-11-15

Family

ID=38006529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043400 Ceased WO2007053792A2 (en) 2005-11-05 2006-11-06 Improving the pharmacokinetics of protease inhibitors and other drugs

Country Status (1)

Country Link
WO (1) WO2007053792A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077317A2 (en) * 2008-12-17 2010-07-08 Amplyx Pharmaceuticals, Inc. Protease inhibitors
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
JP2017505777A (en) 2014-01-29 2017-02-23 シンタ ファーマスーティカルズ コーポレーション Targeted therapeutics
KR20160126078A (en) 2014-03-03 2016-11-01 신타 파마슈티칼스 코프. Targeted therapeutics
MA39483A (en) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp TARGET THERAPEUTIC AGENTS
AU2018289339A1 (en) 2017-06-20 2020-01-02 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
CN114591442B (en) * 2022-03-01 2024-04-19 中国科学院深圳先进技术研究院 Light-regulated protease tool and matched substrate thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571698A (en) * 1988-09-02 1996-11-05 Protein Engineering Corporation Directed evolution of novel binding proteins
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US6921531B2 (en) * 1998-05-22 2005-07-26 The Board Of Trustees Of The Leland Stanford Junior University Administering bifunctional molecules containing a drug moiety and presenter protein ligand for therapy
US20050176758A1 (en) * 1995-02-27 2005-08-11 Norbert W. Bischofberger Novel compounds and methods for synthesis and therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571698A (en) * 1988-09-02 1996-11-05 Protein Engineering Corporation Directed evolution of novel binding proteins
US20050176758A1 (en) * 1995-02-27 2005-08-11 Norbert W. Bischofberger Novel compounds and methods for synthesis and therapy
US6921531B2 (en) * 1998-05-22 2005-07-26 The Board Of Trustees Of The Leland Stanford Junior University Administering bifunctional molecules containing a drug moiety and presenter protein ligand for therapy
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WELLING P. AND DOBRINSKA M.: "Dosing and Bioavailability. Controlled Drug Delivery: Fundamentals and Applications", vol. 2ND ED., 1978, MARCEL DEKKER, INC., NEW YORK *

Also Published As

Publication number Publication date
WO2007053792A2 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
WO2007053792A3 (en) Improving the pharmacokinetics of protease inhibitors and other drugs
AU2003263599A1 (en) Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
EP1650192A4 (en) Quinolone derivative or salt thereof
AU2000264559A1 (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
CY2013023I1 (en) DRUG FOR OVERACTIVE URINARY BLADDER CONTAINING ACETIC ACID ANALYDE DERIVATIVE AS THE ACTIVE INGREDIENT
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
EP2204181A3 (en) Protease inhibitors
AU2003276656A1 (en) Transdermal delivery system for anti-emetic medication
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
WO2003080070A3 (en) Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
EP1619180A4 (en) CaSR ANTAGONIST
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
AU2003245504A1 (en) Pharmaceutical compositions for drugs having ph-dependentsolubility
WO2002089788A3 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
WO2007005941A3 (en) Liver targeted conjugates
WO2003024933A1 (en) 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
EP1602645A4 (en) Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2004071402A3 (en) STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR
WO2008059502A3 (en) Contact lens compositions
WO1999057098A3 (en) Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
WO2001014886A3 (en) Inhibitors of binding between proteins and macromolecular ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837104

Country of ref document: EP

Kind code of ref document: A2